Quotient Sciences
@Quotient_Sci
Followers
977
Following
462
Media
2K
Statuses
4K
Offering formulation development, clinical pharmacology, clinical & commercial manufacturing services to the #pharmaceutical & #biotech industry
Nottingham, England
Joined October 2014
Are you connected with us on our other channels? Check out our handles here and be sure to follow to stay up-to-date on all things #QuotientSciences, including our latest news, announcements, and event info.
0
0
0
RT @pharmacompass: #SpeakPharma – Interview with Denise Sutton, COO and Site Head at @Quotient_Sci’s Nottingham (UK) facility. Sutton disc….
0
2
0
In this #article with @medicine_maker, Dr. Asma Patel, VP of Integrated Development Services, discusses how accelerating first-in-human #clinicaltrials is crucial in #drugdevelopment, especially for orphan drugs treating rare diseases.
0
1
1
RT @MedsforMalaria: #PressRelease The first clinical trial for a long-acting injectable for #malaria prevention by MMV and @Quotient_Sci ha….
0
3
0
In this video interview with @manchempharma, Dr. Andy Lewis, CSO, and Dr. Andrew Parker, Senior Drug Development Consultant, discussed the growing interest in oral #peptides and common challenges faced in #preclinical development at CPHI Milan. Watch here:
0
0
0
Hear from Alejandra Ugalde on what it's like working as a Screening Manager at our Miami, FL facility. Learn more about her #career and experience at #QuotientSciences:
0
0
0
Dr. Andy Lewis, Chief Scientific Officer, and Dr. Stuart Mair, VP of Medical Consulting, reflect on latest developments in GLP-1s as a follow-up to our recent webinar series. Read more here:
0
0
0
In this article with @Clin_Trials, Martin Wing-King, VP and General Manager, discusses the complexity of bringing new treatments to market and how demand for accelerated pathways to first-in-human trials is growing across the pharmaceutical industry.
0
0
0
We are proud to announce the installation of Centillion's™ proprietary Biofoundry-in-a-Box (BiaB™), the first multi-product GMP platform technology for end to end RNA manufacture. Learn more:
0
0
0
Dive into the life of a Principal Formulation Scientist at #QuotientSciences: Jordan Dickens shares more about his career and experience working with us in Nottingham, UK.
0
0
0
Latest News: @MedsforMalaria and Quotient Sciences have begun the first #clinicaltrial at Quotient Sciences' Nottingham, UK facility for a long-acting injectable (LAI) preventive compound for malaria, MMV371.
0
0
0
We have been named a finalist in 2 categories of @FierceBiotech's #FierceCROAwards. These celebrate exceptional achievements and innovations by CROs demonstrating outstanding performance, innovation, and leadership in delivering high-quality R&D services.
0
0
0
Our CEO, Thierry Van Nieuwenhove, spoke with @EPM_Magazine about how #QuotientSciences is innovating to meet the growing demand for more personalized medicine and tracking towards #sustainability goals:
0
0
0
Dr. Helen Baker, Director of Formulation Design, speaks on how ASAPprime® software works and customers can benefit from it to their next drug program:
0
0
0
Latest News: @MedsforMalaria and Quotient Sciences have begun the first #clinicaltrial at Quotient Sciences' Nottingham, UK facility for a long-acting injectable (LAI) preventive compound for malaria, MMV371.
0
0
1
In an interview with @ContractPharma, Thierry Van Nieuwenhove, CEO at Quotient Sciences, discusses emerging trends in the #CDMO industry and the future of #drugdevelopment:
0
0
1
We're proud to partner with @MedsforMalaria to start the first clinical trial for a long-acting injectable form of MMV371. The trial, conducted in healthy volunteers in our Nottingham, UK clinic, marks a significant step toward preventing #malaria in endemic regions.
#PressRelease The first clinical trial for a long-acting injectable for #malaria prevention by MMV and @Quotient_Sci has begun. This innovative treatment could offer up to 3 months of protection with just one injection. Watch to learn more:
0
1
0
#ICYMI: Martin Wing-King, VP and General Manager, Site Head, discusses the capabilities offered on-site at #Reading and expertise that our team offers in #formulationdevelopment for both simple and complex dosage forms. Read part two of our #blog feature:
0
0
0
In our latest #blog, Dr. Helen Baker, Director of Formulation Design, speaks on how our ASAPprime® software works at different stages of the development process and how customers can benefit from adding on analysis to their next drug program.
0
0
1